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lasting less than 30 minutes during the week before infarction. RV infarction was defined
as ST-segment elevation of more than 0.1mV in lead V4R. The PDCF was determined by
simultaneous measurement of mean aorta pressure (Pa), coronary wedge pressure (Pw)
assessed by pressure guidewire: PDCF=Pw/Pa. Sufficient collateral (group 1, n=10) was
defined as PDCF index >24% and insufficient collateral (group 2, n=16) as PDCF<24%.
Results: Baseline characteristics were similar between both groups. Preinfarction angina
was detected less frequently in group 2 than in group 1 (29% vs 89%, p=0.004). RV inf-
arction was observed more frequently in group 2 than in group 1 (71% vs 0%, p<0.001).
Time to reperfusion was not related to PDCF.
Conclusion: Functional coronary collateral flow is responsible for the infrequency of RV
infarction in patients with acute inferior MI.
1026-61 Quantitative Evaluation of Coronary Reperfusion by 
Transthoracic Doppler Echocardiography in Patients 
With Anterior Acute Myocardial Infarction
Souki Lee, Yutaka Otuji, Shinichi Minagoe, Shuichi Hamasaki, Koichi Toyonaga, 
Hachirou Obata, Takurou Takumi, Hitoshi Toda, Chuwa Tei, Kagpshima City Hospital, 
Kagoshima, Japan, Kagoshima University School of Medicine, Kagoshima, Japan
Background: Although transthoracic Doppler echocardiography (TTDE) enables evalua-
tion of distal left anterior descending (LAD) artery flow, its feasibility to evaluate coronary
reperfusion in the acute phase before coronary intervention in patients with acute myo-
cardial infarction (AMI) is not established.We hypothesized that presence or absence of
TIMI 2 or 3 reflow can be evaluated by color TTDE of the distal LAD and good reflow with
less Thrombolysis In Myocardial Infarction (TIMI) frame count by angiography is associ-
ated with preserved diastolic flow velocity of the LAD by pulsed TTDE. Methods: In 47
consecutive patients with a first anterior AMI within 12 hours from the onset, the pres-
ence of antegrade distal LAD flow and its diastolic peak velocity was evaluated by color
and pulsed TTDE and compared with the TIMI frame count by subsequent coronary
angiography. Results: 1) Coronary reperfusion was TIMI 2 to 3 in 23 of 47 patients. Diag-
nosis of TIMI 2 or 3 by the presence of distal LAD reflow by color TTDE had the sensitiv-
ity, specificity, and accuracy of 83%, 87%, and 85%, respectively. 2) In the 19 patients
with visible LAD reflow by color TTDE, the diastolic peak velocity of the LAD flow by
pulsed TTDE showed a significant and inverse correlation with the LAD TIMI frame count
by angiography (r = -0.75, P = 0.0002). The diagnosis of TIMI frame count > 40, express-
ing poorer outcome, by the diastolic peak velocity < 20 cm/sec with pulsed TTDE had a
sensitivity, specificity, and accuracy of 80%, 93%, and 89%, respectively. Conclusion:
TTDE enables noninvasive and quantitative evaluation of the coronary reperfusion in
patients with anterior AMI in the acute phase prior to emergent coronary intervention.
1026-62 Distal Protection Device (PercuSurge) Can Reduce 
Infarct Size in Patients With Acute Myocardial Infarction 
Who Have Ruptured Culprit Plaque
Isamu Mizote, Kazuhisa Kodama, Atsushi Hirayama, Yasunori Ueda, Yuzuru Takano, 
Jyouta Ooyabu, Taku Sakai, osaka police hospital, osaka, Japan
Background: Distal protection device is demonstrated to prevent distal embolism in the
PCI of saphenous vein graft.However, its effectiveness in the PCI of native coronary
artery is unknown. We examined its aspirated material and its effect on infarct size limita-
tion in patients with acute myocardial infarction having or not having ruptured culprit
plaque.
Methods: Consecutive patients (n=39) with acute myocardial infarction were treated by
PCI using distal protection device (PercuSurge). Culprit lesion was observed by angios-
copy and determined whether or not having ruptured plaque. Ruptured plaque was
defined as a disrupted plaque with its content protruded and occupied >50% of lumen.
TAT levels of aspirated blood were measured and compared between patients with and
without ruptured plaque. Control patients were selected matching for gender, age, lesion
site, occlusion time, and whether or not having ruptured plaque. Infarct size evaluated by
peak-CK-MB, and resolution of ST segment elevation (ST-resolution) was compared
between patients treated with distal protection device and their matched control.
Results: Ruptured plaque was detected in 56 patients. TAT levels were significantly
higher in patients with ruptured plaque than in those without ruptured plaque (17.5±7.0
ng/ml vs. 8.3±3.0ng/ml, p=0.006). Infarct size evaluated by peak CK-MB (187±86 U/L vs.
357±232U/L p=0.007) and ST-resolution (66±15% vs. 40±21%, p=0.001) was signifi-
cantly reduced by the use of distal protection device in patients with ruptured plaque, but
not in patients without ruptured plaque (peak-CK-MB; 154±99 U/L vs. 175±116U/L p=ns:
ST-resolution; 63±13% vs. 59±23%, p=ns). Aspirated material were detected more often
(85.7% vs. 54.5%, p=0.038) in patients with ruptured plaque. Aspirated material was
pathologically lipid-rich tissue or platelet and fibrin-rich thrombus.
Conclusions: Distal protection device reduced infarct size in patients with acute myocar-
dial infarction who have ruptured culprit plaque. This result suggests that the infarct size
is increased by the distal embolization of thrombus or lipid-rich material from culprit
lesion.
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1043-41 Baseline Heart Rate Predicts All-Cause Mortality After 
Percutaneous Coronary Intervention
Deepak P. Vivekananthan, Hitinder S. Gurm, Deepak L. Bhatt, Vivek Rajagopal, Michael 
S. Lauer, Stephen G. Ellis, Cleveland Clinic Foundation, Cleveland, OH
Background: Previous studies have demonstrated an association between resting heart
rate (HR) and mortality. However, it is unknown whether revascularization reduces the
risk associated with an elevated baseline HR. We sought to determine the impact of
baseline HR on outcomes after percutaneous coronary intervention (PCI).
Methods and Results: We followed 4580 consecutive patients who underwent PCI at
the Cleveland Clinic Foundation between 1997 through 2001. We excluded patients with
cardiogenic shock, Class III or IV congestive heart failure (CHF), or recent myocardial inf-
arction. The primary endpoint of the study was all-cause mortality. We divided our cohort
into quartiles of baseline HR (see table). Baseline characteristics were similar between
the quartiles except for a higher percentage of patients on beta blockers (BB) in quartile
1. After a median follow-up of 2.4 years, there were 400 deaths (8.7%). There was a sig-
nificant increase in risk of death with increasing quartile of baseline HR (table). After con-
trolling for confounders and BB use, baseline HR remained independently predictive of
all-cause mortality (OR 1.18; 95% CI 1.1-1.2, p<.0001 for each 10-beat increase in HR).
BB use was not an independent predictor of survival in this cohort.
Conclusion: Resting HR, a marker of autonomic tone, is an independent predictor of all-
cause mortality after PCI. Further study is needed to identify therapies to attenuate the
risk associated with autonomic dysfunction in patients with coronary disease. 
1043-42 A Comparison of the Effect of Eptifibatide Plus Heparin 
Versus Bivalirudin on Thrombin Generation and Clot 
Lysis in Patients Undergoing a Percutaneous Coronary 
Intervention
Larry B. Spiotta, Mary V. Jacoski, Melanie M. White, Shila Cholera, Kay Sims, Lisa K. 
Jennings, University of Tennessee Health Science Center, Vascular Biology Center of 
Excellence, Memphis, TN, TAM Clinical Research Consortium, Memphis, TN
Background: Both platelet rich thrombi (white clots) and fibrin rich thrombi (red clots) are
involved in the pathophysiology of acute coronary syndromes and PCI complications.
Eptifibatide, a GPIIb-IIIa antagonist, prevents the formation of platelet rich thrombi,
whereas bivalirudin prevents the stabilization of platelet rich thrombi by fibrin. Bivalirudin
is increasingly being used in the cath lab as a substitute for GPIIb-IIIa antagonists plus
heparin. Previous studies reported increased thrombin generation following cessation of
heparin, whereas no such increase occurred with GPIIb-IIIa antagonists. This study com-
pared the effects of bivalirudin versus eptifibatide plus heparin on thrombin generation
and clot lysis. Methods: Twenty patients scheduled to undergo PCI with either eptifi-
batide (10 patients) or bivalirudin (10 patients) were enrolled. Blood samples were col-
lected at 5 intervals from baseline through 24 hours post treatment. ELISA analyses
assessed levels of prothrombin fragment 1.2 (PF 1.2), fibrinopeptide A (FPA), and D-
dimer. Platelet aggregation by light transmission aggregometry was measured through 4-
6 hours. Results: PF 1.2 levels were unchanged in patients receiving bivalirudin,
whereas those receiving eptifibatide and heparin demonstrated a slight increase in activ-
ity, likely due to cessation of heparin. FPA levels initially decreased with both treatments,
then increased at 24 hours, indicating a resumption of thrombin turnover. D-dimer levels,
a measure of clot lysis, were relatively unchanged with bivalirudin treatment, but
increased over time with eptifibatide and heparin. ADP and TRAP induced platelet aggre-
gation were effectively inhibited by eptifibatide, whereas no consistent inhibition was
observed with bivalirudin. Conclusion: Neither bivalirudin nor eptifibatide increases
thrombin generation, although the combination of heparin with eptifibatide increases
thrombin rebound in some patients. Clot lysis does not appear to improve with bivalirudin
to the extent observed with eptifibatide. This study suggests that eptifibatide combined
with bivalirudin could maximize platelet inhibition, thrombin inhibition, and clot lysis.
Q1
N=1146
Q2
N=1069
Q3
N=1265
Q4
N=1100  P
Mean HR 56 +4 66 +2 74 +3 88 +10
% BB 43% 37% 35% 32% <0.0001
Mortality 5.5% 7.1% 10.2% 12.0% <0.0001
